- Home
- DIBS vs CCCC Comparison
DIBS vs CCCC Comparison
Compare DIBS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DIBS | CCCC |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.7M | 185.1M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DIBS | CCCC |
|---|---|---|
| Price | $4.45 | $3.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $12.20 |
| AVG Volume (30 Days) | 171.2K | ★ 2.9M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.45 | 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,620,000.00 | $35,947,000.00 |
| Revenue This Year | $3.12 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.54 | 1.02 |
| 52 Week Low | $2.35 | $1.21 |
| 52 Week High | $6.62 | $3.95 |
Technical Indicators
Market Signals| Indicator | DIBS | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 60.10 |
| Support Level | $4.38 | $2.37 |
| Resistance Level | $5.74 | $3.82 |
| Average True Range (ATR) | 0.33 | 0.30 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 50.75 | 60.84 |
Price Performance
Historical ComparisonAbout DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.